Peptide Research Glossary

A comprehensive reference covering the terminology encountered across peptide research, from receptor biology and signaling cascades to pharmacology and clinical trial design. Terms are organized by category and alphabetically within each section.

---

Receptors

AMPA Receptor

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors are ionotropic glutamate receptors that mediate fast synaptic transmission in the CNS. They work in concert with NMDA receptors to regulate synaptic strength and plasticity. AMPA receptor trafficking to and from the synapse is a key mechanism underlying long-term potentiation (LTP) and memory formation.

BMP Receptor

Bone morphogenetic protein receptors are serine/threonine kinase receptors that bind BMPs, a subgroup of the TGF-beta superfamily. They play essential roles in bone and cartilage formation, embryonic development, and tissue homeostasis. BMP signaling through these receptors activates SMAD1/5/8 transcription factors to regulate osteoblast differentiation and skeletal patterning.

Calcitonin Receptor

A G protein-coupled receptor (GPCR) that binds the hormone calcitonin, primarily expressed in osteoclasts and kidney cells. Activation inhibits osteoclast-mediated bone resorption, making it a target in osteoporosis research. The receptor also modulates renal calcium handling and has been studied in relation to amylin signaling when complexed with receptor activity-modifying proteins (RAMPs).

CB1 / CB2 (Cannabinoid Receptors)

CB1 receptors are predominantly found in the central nervous system and modulate neurotransmitter release, appetite, pain perception, and mood. CB2 receptors are mainly expressed on immune cells and regulate inflammatory responses and immune cell migration. Both are GPCRs that respond to endocannabinoids such as anandamide and 2-AG, as well as phytocannabinoids.

CCK-A / CCK-B (Cholecystokinin Receptors)

CCK-A (now called CCK1) receptors are expressed primarily in the gastrointestinal tract and mediate satiety signaling, gallbladder contraction, and pancreatic enzyme secretion. CCK-B (CCK2) receptors are found in the brain and stomach, where they regulate anxiety-related behaviors and gastric acid secretion. Both are GPCRs activated by cholecystokinin peptides.

CGRP Receptor

The calcitonin gene-related peptide receptor is a heterodimer of the calcitonin receptor-like receptor (CLR) and RAMP1. CGRP is one of the most potent vasodilators known and plays a central role in migraine pathophysiology. Monoclonal antibodies and small-molecule antagonists targeting this receptor have become breakthrough treatments for migraine prevention.

CXCR4

A chemokine receptor belonging to the GPCR family that binds stromal cell-derived factor 1 (SDF-1/CXCL12). CXCR4 plays critical roles in stem cell homing, immune cell trafficking, and embryonic development. It is also a co-receptor for HIV entry into T-cells and is overexpressed in many cancers, making it a target for anti-metastatic therapies.

EGF Receptor (EGFR)

The epidermal growth factor receptor is a receptor tyrosine kinase that binds EGF and related growth factors. Activation triggers cell proliferation, survival, and differentiation pathways including MAPK/ERK and PI3K/AKT. EGFR mutations and overexpression are common in cancers, and multiple targeted therapies (gefitinib, erlotinib, cetuximab) have been developed against it.

FGF Receptor (FGFR)

Fibroblast growth factor receptors are a family of four receptor tyrosine kinases (FGFR1-4) that bind FGF ligands. They regulate cell growth, differentiation, angiogenesis, and wound healing. FGF signaling is critical in tissue repair and regeneration, and dysregulation is implicated in skeletal disorders and various cancers.

GHS-R (Ghrelin Receptor)

The growth hormone secretagogue receptor is a GPCR predominantly expressed in the hypothalamus and pituitary gland. It is the endogenous receptor for ghrelin, the "hunger hormone," and mediates growth hormone release, appetite stimulation, and energy homeostasis. Synthetic GH secretagogues like GHRP-6 and hexarelin act through this receptor.

GHRH-R (Growth Hormone Releasing Hormone Receptor)

A GPCR expressed on anterior pituitary somatotroph cells that binds GHRH to stimulate growth hormone synthesis and secretion. Activation triggers the cAMP/PKA signaling cascade. Peptides like sermorelin, tesamorelin, and CJC-1295 are synthetic GHRH analogs that act through this receptor to promote pulsatile GH release.

GLP-1R (Glucagon-Like Peptide-1 Receptor)

A GPCR expressed in pancreatic beta cells, the gut, and the central nervous system. Activation by GLP-1 or synthetic agonists (semaglutide, liraglutide, tirzepatide) enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. GLP-1R agonists have become transformative treatments for type 2 diabetes and obesity.

GnRH-R (Gonadotropin-Releasing Hormone Receptor)

A GPCR on anterior pituitary gonadotroph cells that binds GnRH to regulate the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Pulsatile GnRH stimulation maintains reproductive function, while continuous stimulation causes receptor desensitization and suppression of the HPG axis. GnRH agonists and antagonists are used in fertility treatment and hormone-sensitive cancers.

IGF-1R (Insulin-Like Growth Factor 1 Receptor)

A receptor tyrosine kinase that binds IGF-1 and IGF-2, activating PI3K/AKT and MAPK pathways to promote cell growth, survival, and differentiation. It plays a central role in the GH/IGF-1 axis and is critical for normal growth and development. IGF-1R signaling has been implicated in cancer progression and has been explored as a therapeutic target.

Integrin Receptors

A large family of heterodimeric transmembrane receptors composed of alpha and beta subunits that mediate cell adhesion to the extracellular matrix. Integrins transduce mechanical and chemical signals bidirectionally across the cell membrane, regulating cell migration, proliferation, and survival. They are critical in wound healing, angiogenesis, and immune cell trafficking, and several peptide motifs (such as RGD) target integrin binding.

MC1R (Melanocortin 1 Receptor)

A GPCR expressed on melanocytes that binds alpha-MSH to stimulate melanin production and skin pigmentation. It is the primary target of melanotan I (afamelanotide), which promotes eumelanin synthesis for photoprotection. MC1R variants are associated with red hair, fair skin, and increased melanoma susceptibility.

MC3R (Melanocortin 3 Receptor)

A GPCR expressed in the hypothalamus, gut, and immune cells that participates in energy homeostasis and inflammation. MC3R modulates feeding behavior, fat storage, and circadian rhythms. Unlike MC4R, its role appears more related to energy partitioning (fat vs. lean mass) and peripheral immune regulation.

MC4R (Melanocortin 4 Receptor)

A GPCR in the hypothalamus that is a central regulator of appetite and energy balance. Activation by alpha-MSH or synthetic agonists like setmelanotide suppresses appetite, while loss-of-function mutations are the most common monogenic cause of obesity. MC4R is also the receptor through which melanotan II and PT-141 (bremelanotide) exert effects on sexual function.

mTOR (Mechanistic Target of Rapamycin)

A serine/threonine kinase that functions as a central integrator of nutrient availability, growth factor signaling, and cellular energy status. mTOR exists in two complexes: mTORC1 (regulates protein synthesis and cell growth) and mTORC2 (regulates cell survival and cytoskeletal organization). Rapamycin inhibits mTORC1 and has been studied as a geroprotective agent.

NK1R (Neurokinin 1 Receptor)

A GPCR that binds substance P, a neuropeptide involved in pain transmission, inflammation, and emesis. NK1R is expressed in the CNS and peripheral tissues and mediates neurogenic inflammation and nociceptive signaling. Antagonists like aprepitant are used clinically as antiemetics for chemotherapy-induced nausea.

NMDA Receptor

The N-methyl-D-aspartate receptor is a ligand-gated ion channel that requires both glutamate and glycine (or D-serine) for activation. It plays a central role in synaptic plasticity, learning, and memory through its calcium permeability. NMDA receptor dysfunction is implicated in neurodegeneration, chronic pain, and psychiatric disorders, and the receptor is modulated by various peptides and small molecules.

Notch Receptor

A single-pass transmembrane receptor that mediates cell-cell communication through direct contact with Notch ligands (Delta, Jagged) on adjacent cells. Upon activation, the intracellular domain is cleaved and translocates to the nucleus to regulate gene expression. Notch signaling controls cell fate decisions, stem cell maintenance, and tissue homeostasis, with dysregulation linked to cancer and developmental disorders.

Opioid Receptors (Mu, Delta, Kappa)

Three major classes of GPCRs that bind endogenous opioid peptides (endorphins, enkephalins, dynorphins) and exogenous opioid drugs. Mu receptors primarily mediate analgesia and euphoria, delta receptors modulate mood and pain, and kappa receptors are involved in dysphoria and stress responses. Understanding opioid receptor selectivity is essential for developing analgesic peptides with reduced side effects.

PPAR-gamma (Peroxisome Proliferator-Activated Receptor Gamma)

A nuclear receptor and transcription factor that regulates fatty acid storage, glucose metabolism, and adipocyte differentiation. PPAR-gamma activation promotes insulin sensitivity and is the target of thiazolidinedione drugs used in type 2 diabetes. It also modulates inflammation and has been studied in the context of metabolic syndrome and neurodegenerative disease.

Smoothened Receptor

A GPCR-like protein in the Hedgehog signaling pathway that is normally repressed by the Patched receptor. When Hedgehog ligand binds Patched, Smoothened is derepressed and activates Gli transcription factors. This pathway is critical in embryonic development, tissue patterning, and stem cell maintenance, with aberrant activation driving certain cancers (basal cell carcinoma, medulloblastoma).

TGF-beta Receptor

Transforming growth factor-beta receptors are serine/threonine kinases that form heteromeric complexes (Type I and Type II) upon TGF-beta ligand binding. They activate SMAD-dependent and SMAD-independent signaling to regulate cell growth, differentiation, apoptosis, and extracellular matrix production. TGF-beta signaling is central to wound healing and fibrosis, with context-dependent roles in cancer.

TLR2 / TLR4 (Toll-Like Receptors)

Pattern recognition receptors of the innate immune system that detect conserved microbial components. TLR4 recognizes lipopolysaccharide (LPS) from gram-negative bacteria, while TLR2 detects lipoproteins and peptidoglycan from gram-positive bacteria. Activation triggers NF-kappaB and inflammatory cytokine production, connecting innate immunity to adaptive immune responses.

VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)

The primary signaling receptor for VEGF-A, a key driver of angiogenesis. VEGFR2 is a receptor tyrosine kinase expressed on vascular endothelial cells that promotes endothelial cell proliferation, migration, and vessel formation. It is a major therapeutic target in cancer (bevacizumab, ramucirumab) and retinal vascular diseases.

Wnt Receptor (Frizzled)

Frizzled receptors are a family of GPCRs that bind Wnt ligands in cooperation with LRP5/6 co-receptors. Activation initiates the canonical Wnt/beta-catenin pathway, which regulates cell proliferation, stem cell self-renewal, and tissue development. Dysregulated Wnt signaling is implicated in colorectal cancer, bone disorders, and degenerative diseases.

Y1 / Y2 / Y5 Receptors (Neuropeptide Y Receptors)

GPCRs that bind neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP). Y1 receptors stimulate appetite and are involved in anxiety and vasoconstriction. Y2 receptors mediate feedback inhibition of NPY release and are targets for appetite suppression research. Y5 receptors also participate in feeding behavior and energy homeostasis.

---

Signaling Pathways

AMPK Pathway

AMP-activated protein kinase is a cellular energy sensor activated when the AMP:ATP ratio rises during metabolic stress. AMPK promotes catabolic processes (fatty acid oxidation, glucose uptake, autophagy) while inhibiting anabolic processes (protein synthesis via mTORC1 inhibition, lipogenesis). It is a key target in metabolic disease research and is activated by metformin and exercise.

Autophagy (ATG) Pathway

A conserved cellular recycling process in which damaged organelles and misfolded proteins are enclosed in autophagosomes and delivered to lysosomes for degradation. Regulated by ATG (autophagy-related) genes, this pathway maintains cellular homeostasis and is induced by nutrient deprivation, mTORC1 inhibition, and AMPK activation. Dysfunctional autophagy is linked to neurodegeneration, cancer, and aging.

Calcineurin/NFAT Pathway

Calcineurin is a calcium-dependent phosphatase that dephosphorylates NFAT (Nuclear Factor of Activated T-cells), allowing its nuclear translocation and transcriptional activation. This pathway is essential for T-cell activation and immune responses, cardiac hypertrophy, and skeletal muscle fiber-type specification. Immunosuppressants cyclosporine and tacrolimus work by inhibiting calcineurin.

cAMP/PKA Pathway

Cyclic adenosine monophosphate (cAMP) is a second messenger generated by adenylyl cyclase upon GPCR activation. cAMP activates protein kinase A (PKA), which phosphorylates downstream targets including CREB transcription factor. This pathway mediates the actions of many peptide hormones including GHRH, GLP-1, and ACTH, regulating metabolism, gene expression, and hormone secretion.

CREB Signaling

cAMP response element-binding protein is a transcription factor activated by phosphorylation, primarily through PKA but also by MAPK and calcium-dependent kinases. Phosphorylated CREB binds CRE (cAMP response element) sequences in gene promoters to regulate genes involved in neuronal survival, memory consolidation, gluconeogenesis, and neuropeptide expression.

FAK/Paxillin Pathway

Focal adhesion kinase (FAK) is a tyrosine kinase recruited to integrin-mediated focal adhesions upon cell-matrix binding. FAK phosphorylates paxillin and other scaffold proteins to regulate cell migration, survival, and mechanotransduction. This pathway is critical in wound healing, tissue remodeling, and is often hyperactivated in metastatic cancers.

Ferroptosis Pathway

A regulated form of cell death driven by iron-dependent lipid peroxidation, distinct from apoptosis and necrosis. Ferroptosis occurs when glutathione peroxidase 4 (GPX4) activity is insufficient to neutralize lipid hydroperoxides. This pathway has gained attention in cancer therapy (inducing ferroptosis in resistant tumors) and neurodegeneration (protecting neurons from ferroptotic damage).

Hedgehog Pathway

A developmental signaling cascade initiated when Hedgehog ligands (Sonic, Indian, or Desert) bind the Patched receptor, relieving inhibition of Smoothened. Downstream Gli transcription factors then regulate target genes controlling cell proliferation, differentiation, and patterning. Aberrant Hedgehog signaling drives certain cancers, and the pathway is involved in tissue repair and stem cell maintenance.

Hippo/YAP Pathway

A kinase cascade (MST1/2 and LATS1/2) that phosphorylates and inactivates YAP/TAZ transcriptional co-activators, restricting organ growth and promoting apoptosis. When the Hippo pathway is inactive, unphosphorylated YAP enters the nucleus and drives proliferation and survival gene expression. This pathway regulates organ size, stem cell self-renewal, and tissue regeneration, with dysregulation implicated in cancer.

Inflammasome (NLRP3)

A multiprotein complex that assembles in response to danger signals (pathogen-associated and damage-associated molecular patterns) to activate caspase-1. Active caspase-1 cleaves pro-IL-1beta and pro-IL-18 into their mature inflammatory forms and can trigger pyroptosis. NLRP3 inflammasome activation is implicated in gout, atherosclerosis, Alzheimer's disease, and metabolic syndrome.

JAK/STAT Pathway

Janus kinase/signal transducer and activator of transcription is a signaling cascade activated by cytokines, interferons, and growth factors. Ligand binding to cytokine receptors activates JAK kinases, which phosphorylate STAT proteins. Phosphorylated STATs dimerize and translocate to the nucleus to regulate immune function, hematopoiesis, and cell growth. JAK inhibitors (tofacitinib, ruxolitinib) are used in autoimmune and myeloproliferative diseases.

JNK Pathway

c-Jun N-terminal kinases are stress-activated protein kinases in the MAPK superfamily that respond to UV radiation, inflammatory cytokines, and oxidative stress. JNK phosphorylates c-Jun and other transcription factors to regulate apoptosis, inflammation, and cell differentiation. Chronic JNK activation is implicated in insulin resistance, neurodegeneration, and liver disease.

MAPK/ERK Pathway

The mitogen-activated protein kinase/extracellular signal-regulated kinase cascade (Ras-Raf-MEK-ERK) is one of the most studied signaling pathways in cell biology. Activated by growth factors binding receptor tyrosine kinases, it drives cell proliferation, differentiation, and survival. Dysregulation through oncogenic Ras or Raf mutations is found in many cancers, making pathway components key therapeutic targets.

mTORC1 / mTORC2

Two distinct multiprotein complexes formed by the mTOR kinase. mTORC1 (with Raptor) integrates nutrient, energy, and growth factor signals to regulate protein synthesis through S6K and 4E-BP1 phosphorylation, and is sensitive to rapamycin. mTORC2 (with Rictor) regulates cell survival via AKT phosphorylation and cytoskeletal organization, and is relatively rapamycin-insensitive in acute treatment.

NF-kappaB Pathway

Nuclear factor kappa-light-chain-enhancer of activated B cells is a family of transcription factors that regulate inflammation, immunity, cell survival, and proliferation. In the canonical pathway, inflammatory signals activate IKK, which phosphorylates IkappaB for degradation, releasing NF-kappaB to enter the nucleus. Chronic NF-kappaB activation is a hallmark of inflammatory diseases and many cancers.

NO/cGMP Pathway

Nitric oxide synthase (NOS) produces nitric oxide (NO), which diffuses into target cells and activates soluble guanylyl cyclase to produce cyclic GMP (cGMP). cGMP activates protein kinase G (PKG), leading to smooth muscle relaxation and vasodilation. This pathway is critical in cardiovascular function, neurotransmission, and penile erection, and is targeted by phosphodiesterase-5 inhibitors like sildenafil.

Notch Signaling

Cell-contact-dependent signaling initiated when Notch receptors on one cell interact with Delta or Jagged ligands on an adjacent cell. Proteolytic cleavage releases the Notch intracellular domain (NICD), which enters the nucleus to activate transcription of HES and HEY genes. This pathway controls binary cell fate decisions, stem cell maintenance, and is frequently mutated in T-cell acute lymphoblastic leukemia.

Nrf2/ARE Pathway

Nuclear factor erythroid 2-related factor 2 is a transcription factor that, under oxidative stress, dissociates from its inhibitor Keap1 and translocates to the nucleus. There it binds antioxidant response elements (ARE) to upregulate detoxification enzymes (glutathione S-transferase, heme oxygenase-1, NAD(P)H quinone oxidoreductase). This pathway is the master regulator of cellular antioxidant defense and is studied in neuroprotection and aging.

p53 Pathway

The tumor suppressor p53, called the "guardian of the genome," is activated by DNA damage, oncogene activation, and other stress signals. It induces cell cycle arrest, DNA repair, senescence, or apoptosis depending on the severity of damage. p53 is mutated or inactivated in approximately half of all human cancers, making it one of the most important proteins in cancer biology.

PI3K/AKT Pathway

Phosphoinositide 3-kinase generates PIP3 at the cell membrane, recruiting and activating the serine/threonine kinase AKT (protein kinase B). AKT promotes cell survival (inhibiting pro-apoptotic factors), growth (activating mTORC1), and metabolism (enhancing glucose uptake). This pathway is frequently hyperactivated in cancer through PIK3CA mutations or PTEN loss.

PKC Pathway

Protein kinase C is a family of serine/threonine kinases activated by diacylglycerol (DAG) and calcium. PKC isoforms regulate diverse cellular processes including cell proliferation, apoptosis, migration, and immune cell activation. Different isoforms (conventional, novel, atypical) have distinct activation requirements and tissue distributions, making isoform-selective targeting an active area of drug development.

Proteasome Pathway

The ubiquitin-proteasome system is the primary mechanism for targeted protein degradation in eukaryotic cells. Proteins marked with polyubiquitin chains are recognized and degraded by the 26S proteasome. This pathway regulates cell cycle progression, transcription factor turnover, and immune antigen presentation. Proteasome inhibitors (bortezomib) are used in multiple myeloma treatment.

Src Kinase Pathway

Src is a non-receptor tyrosine kinase that integrates signals from multiple receptor types (integrins, GPCRs, receptor tyrosine kinases) to regulate cell adhesion, migration, and proliferation. It was the first proto-oncogene discovered and remains relevant in cancer biology. Src family kinases (SFKs) also play roles in bone remodeling, immune function, and neural development.

TGF-beta/SMAD Pathway

Transforming growth factor-beta signals through type I and type II serine/threonine kinase receptors, which phosphorylate receptor-regulated SMADs (SMAD2/3). These form complexes with SMAD4 and translocate to the nucleus to regulate transcription of genes controlling cell growth, differentiation, and extracellular matrix production. This pathway is central to fibrosis, wound healing, and has dual roles in cancer (tumor suppression early, promotion late).

Wnt/Beta-Catenin Pathway

In the canonical Wnt pathway, Wnt ligands bind Frizzled receptors and LRP5/6 co-receptors, inhibiting the beta-catenin destruction complex (APC, Axin, GSK-3beta). Stabilized beta-catenin accumulates and enters the nucleus to activate TCF/LEF target genes driving proliferation and stemness. This pathway is essential for intestinal stem cell maintenance, bone formation, and is constitutively active in most colorectal cancers through APC mutations.

---

Molecular Biology Terms

Actin

A globular protein (G-actin) that polymerizes into filamentous actin (F-actin), forming a major component of the cytoskeleton. Actin filaments provide mechanical support, drive cell motility and shape changes, and are essential for muscle contraction. Dynamic actin remodeling is regulated by numerous binding proteins and signaling pathways, including Rho GTPases.

Chaperone Protein

Molecular chaperones assist in the proper folding of newly synthesized proteins and prevent aggregation of misfolded proteins under stress conditions. They include heat shock proteins (HSP70, HSP90), chaperonins (GroEL/GroES, TRiC), and small heat shock proteins. Chaperone dysfunction contributes to protein aggregation diseases such as Alzheimer's and Parkinson's.

Chromatin Remodeling

The dynamic modification of chromatin architecture by ATP-dependent remodeling complexes (SWI/SNF, ISWI, CHD, INO80) that reposition or eject nucleosomes. This process regulates access of transcription factors and RNA polymerase to DNA, controlling gene expression without changing the DNA sequence. Mutations in chromatin remodeling factors are common in cancer.

Collagen

The most abundant protein in mammals, forming the primary structural component of connective tissues including skin, bone, tendon, and cartilage. Collagen molecules assemble into a triple-helix structure and further organize into fibrils and fibers. At least 28 types of collagen exist, with type I being most abundant. Peptides like GHK-Cu are studied for their ability to stimulate collagen synthesis.

DNA Methylation

An epigenetic modification in which a methyl group is added to cytosine bases, primarily at CpG dinucleotides, by DNA methyltransferases (DNMTs). Methylation of gene promoter regions typically represses transcription by preventing transcription factor binding or recruiting methyl-binding proteins. DNA methylation patterns change with age and are used in epigenetic clock calculations of biological age.

Elastin

A highly elastic structural protein found in connective tissues that allows organs like the lungs, arteries, and skin to stretch and recoil. Elastin is produced primarily during development by fibroblasts and smooth muscle cells and has very slow turnover in adults. Loss of elastin integrity contributes to wrinkle formation, arterial stiffness, and emphysema with aging.

Epigenetics

The study of heritable changes in gene expression that do not involve alterations to the DNA sequence itself. Major epigenetic mechanisms include DNA methylation, histone modifications, and non-coding RNA regulation. Epigenetic changes accumulate with age and environmental exposures, and epigenetic reprogramming is a frontier in longevity research.

Extracellular Matrix (ECM)

A complex network of proteins (collagen, elastin, fibronectin, laminin) and carbohydrates (glycosaminoglycans, proteoglycans) that provides structural and biochemical support to surrounding cells. The ECM regulates cell behavior through mechanical signaling and growth factor sequestration. ECM remodeling by matrix metalloproteinases (MMPs) is central to wound healing, fibrosis, and cancer metastasis.

Fibronectin

A high-molecular-weight glycoprotein that binds integrins and extracellular matrix components to mediate cell adhesion, migration, and differentiation. Fibronectin exists in soluble (plasma) and insoluble (tissue) forms and is critical for wound healing and embryonic development. It contains the RGD (Arg-Gly-Asp) motif that many synthetic peptides mimic for biomaterial applications.

Gene Promoter

A region of DNA upstream of a gene that contains binding sites for RNA polymerase and transcription factors to initiate transcription. Promoters include core elements (TATA box, initiator) and regulatory elements (enhancers, silencers) that determine when, where, and how much a gene is expressed. Epigenetic modifications at promoter regions are key regulators of gene activity.

Glycosaminoglycan (GAG)

Long unbranched polysaccharides consisting of repeating disaccharide units, found on cell surfaces and in the extracellular matrix. Major GAGs include hyaluronic acid, heparan sulfate, chondroitin sulfate, and keratan sulfate. They bind water to provide tissue hydration and cushioning, and interact with growth factors and cytokines to modulate signaling.

Heat Shock Protein (HSP)

A family of molecular chaperones upregulated in response to heat, oxidative stress, and other cellular insults. HSP70 and HSP90 are among the best characterized, assisting in protein folding, preventing aggregation, and targeting damaged proteins for degradation. HSPs are being studied in the context of aging, neurodegeneration, and cancer immunotherapy.

Histone Acetylation

The addition of acetyl groups to lysine residues on histone proteins by histone acetyltransferases (HATs). Acetylation neutralizes the positive charge of histones, relaxing chromatin structure and promoting gene transcription. Histone deacetylases (HDACs) remove acetyl groups to repress gene expression. HDAC inhibitors are used in cancer therapy and are being studied in aging research.

hTERT (Human Telomerase Reverse Transcriptase)

The catalytic subunit of the enzyme telomerase, which adds TTAGGG repeat sequences to chromosome ends to counteract telomere shortening. Most somatic cells have low or absent hTERT expression, leading to progressive telomere attrition with each cell division. Reactivation of hTERT is a hallmark of cancer cells and a target in longevity research; the peptide epitalon is studied for its potential to activate telomerase.

Laminin

A major glycoprotein component of basement membranes that mediates cell adhesion, migration, and differentiation through integrin and non-integrin receptors. Laminins are heterotrimeric proteins composed of alpha, beta, and gamma chains, forming at least 16 known isoforms. They are essential for tissue architecture and play critical roles in neural development and muscle function.

mRNA (Messenger RNA)

A single-stranded RNA molecule transcribed from DNA that carries the genetic code to ribosomes for protein synthesis. mRNA is processed through 5' capping, splicing, and 3' polyadenylation before translation. mRNA technology gained prominence through COVID-19 vaccines and is being explored for peptide and protein therapeutic delivery.

Proteasome

A large protein complex (26S) that degrades ubiquitin-tagged proteins into small peptides, serving as the cell's primary protein disposal system. The 20S catalytic core cleaves peptide bonds, while 19S regulatory caps recognize ubiquitinated substrates. Proteasome function declines with age, contributing to the accumulation of damaged proteins and loss of proteostasis.

Proteoglycan

Heavily glycosylated proteins consisting of a core protein with one or more covalently attached glycosaminoglycan chains. Found on cell surfaces and in the extracellular matrix, proteoglycans regulate growth factor signaling, tissue hydration, and structural integrity. Examples include aggrecan (cartilage), syndecan, and perlecan (basement membranes).

Ribosome

A large macromolecular complex composed of ribosomal RNA and proteins that catalyzes protein synthesis (translation) by reading mRNA codons and assembling amino acid chains. Eukaryotic ribosomes (80S) consist of 40S and 60S subunits. Ribosome biogenesis is tightly regulated by mTORC1, connecting nutrient sensing to translational capacity.

siRNA (Small Interfering RNA)

Short double-stranded RNA molecules (20-25 nucleotides) that silence gene expression through the RNA interference (RNAi) pathway. siRNA guides the RISC complex to complementary mRNA sequences for degradation, preventing protein translation. siRNA therapeutics (patisiran) have been approved for clinical use and represent a tool for studying peptide-related gene function.

Telomerase

A ribonucleoprotein enzyme complex that extends telomeres by adding TTAGGG repeats using its RNA template component (TERC) and catalytic subunit (hTERT). Active in stem cells, germ cells, and most cancer cells, telomerase counteracts the end-replication problem. Research peptides like epitalon are investigated for their potential to modulate telomerase activity and influence cellular aging.

Telomere

Repetitive TTAGGG nucleotide sequences at chromosome ends that protect genomic DNA from degradation and fusion during cell division. Telomeres shorten with each replication cycle due to the end-replication problem, and critically short telomeres trigger cellular senescence or apoptosis. Telomere length is considered a biomarker of biological aging and is influenced by lifestyle factors and certain peptides.

Transcription Factor

A protein that binds specific DNA sequences to regulate gene transcription by promoting or blocking RNA polymerase recruitment. Transcription factors can be activated by phosphorylation, ligand binding, or proteolytic processing, and often function as dimers or larger complexes. Examples relevant to peptide biology include CREB, NF-kappaB, p53, and STAT proteins.

Tubulin

A globular protein that polymerizes into microtubules, cylindrical structures that form the mitotic spindle, provide intracellular transport tracks, and maintain cell shape. Alpha and beta tubulin heterodimers assemble dynamically, and microtubule-targeting drugs (taxanes, vinca alkaloids) are major chemotherapeutics. Tubulin post-translational modifications regulate microtubule stability and motor protein binding.

Ubiquitin

A small 76-amino-acid protein that is covalently attached to target proteins through an enzymatic cascade (E1, E2, E3 ligases) to mark them for proteasomal degradation, alter their activity, or change their localization. Polyubiquitin chains linked through different lysine residues encode distinct signals. The ubiquitin system regulates virtually all cellular processes and its dysfunction contributes to neurodegeneration and cancer.

---

Cell Biology

Apoptosis

Programmed cell death executed through intrinsic (mitochondrial) or extrinsic (death receptor) pathways, resulting in orderly cellular dismantlement without inflammation. Characterized by caspase activation, DNA fragmentation, cell shrinkage, and membrane blebbing. Apoptosis is essential for development and tissue homeostasis, and its dysregulation contributes to cancer (insufficient apoptosis) or neurodegeneration (excessive apoptosis).

Autophagy

A conserved cellular self-digestion process in which cytoplasmic components and damaged organelles are sequestered in double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. Autophagy maintains cellular homeostasis, is induced by fasting and caloric restriction, and declines with age. Enhancing autophagy is a strategy explored in longevity research.

B-cell

Lymphocytes of the adaptive immune system that mature in bone marrow and produce antibodies (immunoglobulins) upon antigen activation. B-cells can differentiate into plasma cells (antibody factories) or memory B-cells (long-term immunity). They also function as antigen-presenting cells and are central to vaccine-induced and natural humoral immunity.

Chondrocyte

The only cell type found in healthy cartilage, responsible for producing and maintaining the cartilaginous matrix of collagen and proteoglycans. Chondrocytes reside in low-oxygen environments and have limited regenerative capacity. Peptides like BPC-157 and growth factors are studied for their potential to support chondrocyte function and cartilage repair.

Dendritic Cell

Professional antigen-presenting cells that serve as the bridge between innate and adaptive immunity. Dendritic cells capture antigens in peripheral tissues, process them, and migrate to lymph nodes where they present peptide-MHC complexes to T-cells, initiating adaptive immune responses. They are central to vaccine development and cancer immunotherapy.

Endothelial Cell

Cells that line the interior surface of blood vessels and lymphatic vessels, forming the endothelium. They regulate vascular tone, permeability, angiogenesis, coagulation, and immune cell trafficking. Endothelial dysfunction is a key early event in atherosclerosis, and VEGF signaling through endothelial cells drives new blood vessel formation.

Fibroblast

The most common cell type in connective tissue, responsible for producing extracellular matrix components including collagen, elastin, and fibronectin. Fibroblasts are activated during wound healing to become myofibroblasts, which contract wounds and deposit matrix. They are primary targets for anti-aging peptides like GHK-Cu that aim to restore youthful matrix production.

Keratinocyte

The predominant cell type in the epidermis (outermost skin layer), responsible for producing keratin and forming the protective skin barrier. Keratinocytes originate in the basal layer and differentiate as they migrate upward, eventually forming the cornified (dead) layer. They also produce antimicrobial peptides and cytokines, contributing to skin immune defense.

Macrophage

Innate immune cells derived from monocytes that phagocytose pathogens, dead cells, and debris. Macrophages exist on a spectrum between M1 (pro-inflammatory, antimicrobial) and M2 (anti-inflammatory, tissue repair) polarization states. They play critical roles in wound healing, host defense, and chronic inflammation, and are influenced by various peptide signals including thymosin beta-4.

Mast Cell

Tissue-resident immune cells packed with granules containing histamine, heparin, proteases, and cytokines. Upon activation (classically through IgE cross-linking), mast cells degranulate and release inflammatory mediators that drive allergic reactions, anaphylaxis, and host defense against parasites. They also participate in wound healing and tissue remodeling.

Meiosis

A specialized form of cell division that produces four haploid gametes (eggs or sperm) from a single diploid cell, involving two sequential divisions and genetic recombination through crossing over. Meiosis ensures genetic diversity and proper chromosome number in sexually reproducing organisms. Errors in meiosis lead to aneuploidy and conditions such as Down syndrome.

Mitosis

The process of nuclear division in eukaryotic cells that produces two genetically identical daughter cells. It consists of prophase, metaphase, anaphase, and telophase, followed by cytokinesis. Mitosis is tightly regulated by cyclin-CDK complexes and checkpoints that ensure accurate chromosome segregation, with dysregulation leading to cancer.

NK Cell (Natural Killer Cell)

Innate lymphocytes that provide rapid immune responses against virus-infected and tumor cells without prior sensitization. NK cells recognize stressed cells through a balance of activating and inhibitory receptors and kill targets through perforin/granzyme pathways or death receptor interactions. They are being harnessed in cancer immunotherapy and are modulated by various peptide factors including thymosin alpha-1.

Osteoblast

Bone-forming cells derived from mesenchymal stem cells that synthesize and mineralize the bone matrix (osteoid). Osteoblasts produce type I collagen, osteocalcin, and alkaline phosphatase, and respond to growth factors, hormones (PTH, estrogen), and mechanical loading. Some osteoblasts become embedded in bone matrix as osteocytes, which act as mechanosensors.

Osteoclast

Large multinucleated cells derived from monocyte/macrophage precursors that resorb bone by secreting acid and proteolytic enzymes (cathepsin K) into a sealed resorption lacuna. Osteoclast activity is regulated by RANKL/OPG balance and is inhibited by calcitonin. Excessive osteoclast activity leads to osteoporosis, while insufficient activity causes osteopetrosis.

Progenitor Cell

A partially differentiated cell with limited self-renewal capacity that is committed to producing one or a few specific cell types. Unlike stem cells, progenitor cells are more restricted in their differentiation potential. Examples include satellite cells (muscle progenitors), transit-amplifying cells in the gut, and neural progenitor cells in the brain.

Satellite Cell

Muscle-resident stem/progenitor cells located between the sarcolemma and basal lamina of muscle fibers. Normally quiescent, satellite cells are activated by muscle injury or exercise to proliferate, differentiate, and fuse with existing muscle fibers or form new ones. They are essential for muscle regeneration and are influenced by growth factors including IGF-1 and HGF.

Senescence

A state of permanent cell cycle arrest triggered by telomere shortening, DNA damage, oncogene activation, or oxidative stress. Senescent cells remain metabolically active and secrete the senescence-associated secretory phenotype (SASP), a cocktail of pro-inflammatory cytokines, proteases, and growth factors. Accumulation of senescent cells with age contributes to tissue dysfunction and chronic inflammation.

Stem Cell

An undifferentiated cell capable of self-renewal and differentiation into specialized cell types. Embryonic stem cells are pluripotent (can form any cell type), while adult stem cells are typically multipotent (limited lineage potential). Stem cell exhaustion is a hallmark of aging, and maintaining stem cell pools through peptide and growth factor signaling is an active research area.

T-cell

Lymphocytes that mature in the thymus and mediate cellular adaptive immunity. Major subtypes include CD4+ helper T-cells (coordinate immune responses), CD8+ cytotoxic T-cells (kill infected/tumor cells), and regulatory T-cells (suppress immune responses). T-cell function declines with age (immunosenescence) and can be modulated by thymic peptides like thymosin alpha-1 and thymulin.

---

Pharmacology

Agonist

A substance that binds to and activates a receptor, mimicking the effect of the natural ligand. Full agonists produce maximal receptor activation, while partial agonists produce submaximal responses even at full receptor occupancy. Many therapeutic peptides function as receptor agonists, such as GLP-1 receptor agonists (semaglutide) and GHRH agonists (sermorelin).

Allosteric Modulator

A substance that binds a receptor at a site distinct from the orthosteric (primary ligand) binding site, altering the receptor's response to its natural ligand. Positive allosteric modulators (PAMs) enhance receptor activity, while negative allosteric modulators (NAMs) reduce it. Allosteric modulation offers advantages of preserved physiological signaling patterns and reduced receptor desensitization.

Antagonist

A substance that binds to a receptor without activating it, blocking the binding and effect of agonists. Competitive antagonists compete for the same binding site as the agonist, while non-competitive antagonists bind elsewhere. Examples include GnRH antagonists (degarelix) and CGRP receptor antagonists (rimegepant) used in migraine treatment.

Bioavailability

The fraction of an administered dose of a substance that reaches systemic circulation in its active form. Intravenous administration has 100% bioavailability by definition. Oral peptide bioavailability is typically very low (often less than 1%) due to enzymatic degradation and poor intestinal absorption, which is why most peptides are administered by injection.

Biologic

A therapeutic product derived from or consisting of biological molecules, including monoclonal antibodies, recombinant proteins, peptides, and nucleic acid therapies. Biologics are typically large, complex molecules produced by living cells, as distinct from small-molecule drugs made by chemical synthesis. They generally require parenteral administration and cold-chain storage.

Blood-Brain Barrier (BBB)

A highly selective semipermeable border of endothelial cells linked by tight junctions that separates the circulating blood from the brain extracellular fluid. The BBB restricts passage of most molecules, protecting the brain but also limiting drug delivery. Strategies to cross the BBB include receptor-mediated transcytosis, cell-penetrating peptides, and focused ultrasound.

Clearance

The volume of plasma from which a drug is completely removed per unit time, a key pharmacokinetic parameter reflecting the body's efficiency at eliminating a substance. Renal clearance and hepatic clearance are the two major routes. Peptides are often rapidly cleared by renal filtration and enzymatic degradation, necessitating modifications (PEGylation, lipidation, Fc fusion) to extend their duration of action.

EC50

The effective concentration of a drug that produces 50% of its maximal effect, a measure of potency. A lower EC50 indicates higher potency. EC50 is determined from dose-response curves and is used to compare the potencies of different agonists at the same receptor or the same drug at different targets.

First-Pass Metabolism

The metabolism of an orally administered drug by gastrointestinal and hepatic enzymes before it reaches systemic circulation. Peptides are particularly susceptible to first-pass degradation by proteases in the gut and liver. This is a primary reason oral peptide delivery is challenging and why technologies like SNAC (used with oral semaglutide) and enteric coatings are being developed.

Half-Life

The time required for the plasma concentration of a drug to decrease by 50%. Peptide half-lives range from minutes (most native peptides) to days or weeks (PEGylated or lipidated analogs). Understanding half-life is essential for determining dosing frequency and achieving consistent therapeutic levels.

IC50

The inhibitory concentration of a substance that reduces a biological process by 50%, commonly used to measure the potency of enzyme inhibitors or receptor antagonists. A lower IC50 indicates greater inhibitory potency. IC50 values are context-dependent and can vary with assay conditions, substrate concentrations, and incubation times.

Loading Dose

An initial higher dose of a drug administered to rapidly achieve therapeutic plasma concentrations before transitioning to a maintenance dose. Loading doses are particularly relevant for drugs with long half-lives that would otherwise take multiple dosing intervals to reach steady state. Some peptide protocols use loading dose strategies to saturate receptors more quickly.

Pharmacodynamics (PD)

The study of what a drug does to the body: its biochemical and physiological effects, mechanisms of action, and the relationship between drug concentration and effect. For peptides, pharmacodynamics encompasses receptor binding, signaling pathway activation, and downstream biological responses such as hormone release, gene expression changes, and tissue effects.

Pharmacokinetics (PK)

The study of what the body does to a drug: its absorption, distribution, metabolism, and excretion (ADME). Peptide pharmacokinetics present unique challenges including rapid proteolytic degradation, poor oral absorption, short plasma half-lives, and limited tissue distribution. Chemical modifications and advanced delivery systems aim to improve peptide PK profiles.

Prodrug

An inactive or less active compound that is converted to its active form by enzymatic or chemical processes in the body. Prodrug strategies for peptides include ester prodrugs for improved oral absorption, protease-activated prodrugs for targeted delivery, and depot formulations that slowly release active peptide at the injection site.

Receptor Desensitization

A reduction in receptor responsiveness following prolonged or repeated agonist exposure. Mechanisms include receptor phosphorylation, beta-arrestin recruitment, receptor internalization, and downregulation of receptor expression. Desensitization is clinically relevant for peptide hormones: continuous GnRH exposure causes pituitary desensitization, while pulsatile delivery maintains receptor sensitivity.

Steady State

The condition in which the rate of drug administration equals the rate of elimination, resulting in a stable plasma concentration over time. Steady state is typically achieved after 4-5 half-lives of repeated dosing. For peptides with modified half-lives (like once-weekly semaglutide), reaching steady state may take several weeks.

Tachyphylaxis

A rapid decrease in response to repeated doses of a drug, occurring more quickly and completely than typical tolerance. Tachyphylaxis can result from receptor depletion, rapid desensitization, or depletion of downstream signaling mediators. It is distinct from tolerance, which develops more gradually, and is an important consideration in peptide dosing protocols.

Therapeutic Index

The ratio of the toxic dose to the therapeutic dose (TD50/ED50), indicating the margin of safety for a drug. A large therapeutic index means a wide range between effective and toxic doses. Most peptide therapeutics have favorable therapeutic indices compared to small molecules due to their high target specificity, though off-target effects can still occur.

Volume of Distribution (Vd)

A pharmacokinetic parameter that relates the total amount of drug in the body to its plasma concentration. A large Vd indicates extensive tissue distribution, while a small Vd suggests the drug remains mainly in the plasma. Most peptides have small volumes of distribution due to their hydrophilicity and large molecular size, limiting their ability to penetrate tissues.

---

Peptide Chemistry

Acetylation

The addition of an acetyl group (CH3CO) to a molecule, commonly at the N-terminus of peptides. N-terminal acetylation protects peptides from aminopeptidase degradation, increasing metabolic stability and half-life. It can also influence receptor binding affinity and peptide folding. Many synthetic research peptides are acetylated to improve their pharmacokinetic properties.

Alpha Helix

A common secondary structure in proteins and peptides in which the polypeptide chain coils into a right-handed helical shape stabilized by hydrogen bonds between the backbone carbonyl of residue i and the amide NH of residue i+4. Alpha helices are found in many biologically active peptides and are important for receptor interaction. Stapled peptides use chemical crosslinks to stabilize alpha-helical structure.

Amidation

The modification of a peptide's C-terminus from a free carboxyl group (-COOH) to an amide group (-CONH2). C-terminal amidation is a common post-translational modification in bioactive peptides (over half of known neuropeptides are amidated). It protects against carboxypeptidase degradation and often enhances receptor binding affinity and biological activity.

Amino Acid

The building blocks of peptides and proteins, consisting of an amino group, a carboxyl group, a hydrogen atom, and a distinctive side chain (R group) bonded to a central carbon atom. Twenty standard amino acids are encoded by DNA, each with unique chemical properties. Non-standard and synthetic amino acids are used in peptide chemistry to improve stability, potency, or selectivity.

Bacteriostatic Water

Sterile water containing 0.9% benzyl alcohol as a preservative that inhibits bacterial growth after the vial is opened. It is the standard diluent for reconstituting lyophilized peptides for research use. Unlike sterile water for injection, bacteriostatic water allows multiple uses from the same vial, typically for up to 28 days after opening.

Beta Sheet

A secondary protein structure formed when two or more polypeptide strands align side-by-side and are connected by hydrogen bonds between backbone atoms. Beta sheets can be parallel or antiparallel and provide structural rigidity. Amyloid fibrils in neurodegenerative diseases are composed of cross-beta sheet structures, making beta-sheet-disrupting peptides a therapeutic strategy.

C-terminus

The end of a peptide or protein chain that has a free carboxyl group (-COOH), representing the last amino acid added during ribosomal synthesis. The C-terminus is a common site for post-translational modifications including amidation and GPI anchor attachment. Many peptide drugs are modified at the C-terminus to improve stability or activity.

Cyclization

The formation of a cyclic peptide structure through bonds between the N-terminus and C-terminus (head-to-tail), between side chains, or between a terminus and a side chain. Cyclization constrains peptide conformation, often increasing receptor selectivity, metabolic stability, and membrane permeability compared to linear counterparts. Examples include cyclosporine and many antimicrobial peptides.

Diluent

A liquid used to dissolve or dilute a substance, in peptide research referring to the solvent used to reconstitute lyophilized peptides. Common diluents include bacteriostatic water, sterile water, normal saline, and acetic acid solutions. The choice of diluent depends on the peptide's solubility characteristics and intended use.

Disulfide Bond

A covalent bond formed between the sulfur atoms of two cysteine residues, either within a single peptide (intramolecular) or between separate chains (intermolecular). Disulfide bonds stabilize three-dimensional structure and are critical for the biological activity of peptides like insulin (two interchain and one intrachain disulfide bond) and oxytocin. They are formed in oxidizing environments such as the endoplasmic reticulum.

Fmoc Chemistry

Fluorenylmethyloxycarbonyl chemistry is the most widely used protecting group strategy in solid-phase peptide synthesis. The Fmoc group protects the alpha-amino group during chain assembly and is removed by piperidine under mild basic conditions, while side-chain protecting groups are removed by acid treatment after chain assembly. Fmoc SPPS allows synthesis of peptides up to about 50 amino acids.

HPLC (High-Performance Liquid Chromatography)

An analytical and preparative technique used to separate, identify, and purify components of a peptide mixture based on their interactions with a stationary phase column and a mobile phase solvent. Reversed-phase HPLC (RP-HPLC) is the standard method for peptide purification and purity assessment. Peptide purity is typically reported as the percentage of the main peak on an HPLC chromatogram.

Lyophilization

Freeze-drying: a dehydration process in which a peptide solution is frozen and then subjected to reduced pressure, allowing the ice to sublimate directly to vapor. Lyophilization produces a stable, dry powder that can be stored long-term at low temperatures. Most research peptides are supplied as lyophilized powders that require reconstitution before use.

Mass Spectrometry (MS)

An analytical technique that measures the mass-to-charge ratio of ions to identify and characterize molecules. In peptide research, mass spectrometry (MALDI-TOF, ESI-MS, tandem MS) is used to confirm molecular weight, verify sequence, identify post-translational modifications, and assess purity. It is an essential quality control tool for synthetic peptides.

N-terminus

The end of a peptide or protein chain that has a free amino group (-NH2), representing the first amino acid incorporated during ribosomal synthesis. The N-terminus is susceptible to aminopeptidase degradation, which is why many synthetic peptides are acetylated at this position. N-terminal modifications can also influence receptor binding and biological activity.

PEGylation

The covalent attachment of polyethylene glycol (PEG) polymer chains to peptides or proteins. PEGylation increases hydrodynamic radius (reducing renal clearance), shields from proteolytic degradation, and reduces immunogenicity. This modification extends the circulating half-life of peptide therapeutics, allowing less frequent dosing. Examples include PEGylated interferons and growth hormone formulations.

Peptide Bond

The covalent amide bond formed between the carboxyl group of one amino acid and the amino group of another, with the release of water (condensation reaction). Peptide bonds have partial double-bond character due to resonance, making them planar and relatively rigid. They are the fundamental linkages that join amino acids in peptides and proteins.

Post-Translational Modification (PTM)

Chemical modifications made to a protein or peptide after its ribosomal synthesis. Common PTMs include phosphorylation, glycosylation, acetylation, amidation, methylation, ubiquitination, and disulfide bond formation. PTMs regulate protein function, localization, stability, and interactions, and are crucial for the biological activity of many endogenous peptides.

Reconstitution

The process of dissolving a lyophilized (freeze-dried) peptide powder in an appropriate diluent to create a solution for use. Proper reconstitution requires adding diluent slowly along the vial wall and gently swirling (not shaking) to avoid denaturing the peptide. The reconstituted solution should be stored refrigerated and used within a defined timeframe.

Solid-Phase Peptide Synthesis (SPPS)

A method developed by Bruce Merrifield in which peptides are assembled on an insoluble resin support, with amino acids added one at a time from the C-terminus to the N-terminus. Each cycle involves deprotection, coupling, and washing steps. SPPS revolutionized peptide chemistry by enabling efficient synthesis and purification, and remains the standard manufacturing method for research and therapeutic peptides.

---

Aging and Longevity

Altered Intercellular Communication

A hallmark of aging characterized by changes in cell-to-cell signaling, including increased inflammatory signaling (inflammaging), altered endocrine communication, and changes in the extracellular environment. Age-related shifts from regenerative to inflammatory signaling contribute to tissue dysfunction. Strategies to restore youthful intercellular communication include senolytic therapy and anti-inflammatory interventions.

Biological Age vs. Chronological Age

Chronological age is the time elapsed since birth, while biological age reflects the functional state of an organism's cells and tissues. Biological age can be estimated using epigenetic clocks (DNA methylation patterns), telomere length, composite biomarker panels, and functional assessments. Interventions that reduce biological age relative to chronological age are considered geroprotective.

Cellular Senescence

A stable cell cycle arrest triggered by various stressors including telomere shortening (replicative senescence), DNA damage, and oncogene activation. Senescent cells accumulate with age and secrete the SASP, driving chronic inflammation and tissue dysfunction. Clearing senescent cells with senolytics or modifying their secretory phenotype with senomorphics are promising anti-aging strategies.

Deregulated Nutrient Sensing

A hallmark of aging involving dysfunction in the pathways that detect and respond to nutrient availability, including insulin/IGF-1 signaling, mTOR, AMPK, and sirtuins. Paradoxically, reduced nutrient signaling (as occurs with caloric restriction) tends to extend lifespan, while chronic overactivation promotes aging. This hallmark connects metabolic disease to the aging process.

Epigenetic Drift

The progressive accumulation of changes in DNA methylation, histone modifications, and chromatin organization that occurs with aging, independent of DNA sequence changes. Epigenetic drift leads to altered gene expression patterns, loss of cell identity, and impaired cellular function. Epigenetic reprogramming (partial or full) is being explored as a strategy to reverse aspects of aging.

Genomic Instability

A hallmark of aging characterized by the accumulation of DNA damage from exogenous (UV, chemicals) and endogenous (replication errors, reactive oxygen species) sources throughout life. Despite robust DNA repair mechanisms, unrepaired damage leads to mutations, chromosomal aberrations, and gene expression changes. Genomic instability drives cellular dysfunction, cancer predisposition, and age-related decline.

Geroprotector

Any intervention (compound, lifestyle modification, or therapy) that targets fundamental aging mechanisms to delay age-related decline and extend healthspan. Candidate geroprotectors include rapamycin (mTOR inhibition), metformin (AMPK activation), senolytics (senescent cell clearance), and various peptides including epitalon and humanin. The term encompasses pharmacological and non-pharmacological approaches.

Hallmarks of Aging

A framework of nine (later expanded to twelve) interconnected biological processes that drive aging, as defined by Lopez-Otin et al. (2013, updated 2023). The original nine hallmarks are genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Additional hallmarks include disabled macroautophagy, chronic inflammation, and dysbiosis.

Inflammaging

Chronic, sterile, low-grade inflammation that increases with age in the absence of overt infection. Driven by senescent cells (SASP), gut barrier dysfunction, immunosenescence, and cellular debris, inflammaging elevates baseline levels of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta). It is a major risk factor for age-related diseases including cardiovascular disease, diabetes, neurodegeneration, and cancer.

Mitochondrial Dysfunction

A hallmark of aging characterized by declining mitochondrial function, including reduced oxidative phosphorylation efficiency, increased ROS production, mtDNA mutations, and altered mitochondrial dynamics (fission/fusion balance). Mitochondrial dysfunction impairs cellular energy production and contributes to tissue decline, sarcopenia, and neurodegenerative disease. Peptides like SS-31 (elamipretide) and humanin target mitochondrial function.

Proteostasis (Loss of)

Proteostasis refers to the maintenance of protein homeostasis through balanced protein synthesis, folding, and degradation. A hallmark of aging, loss of proteostasis involves declining chaperone function, impaired proteasome and autophagy activity, and accumulation of misfolded and aggregated proteins. Protein aggregation diseases (Alzheimer's, Parkinson's, Huntington's) exemplify the consequences of proteostasis failure.

Senomorphics

Compounds that suppress the harmful effects of senescent cells without killing them, primarily by modulating the senescence-associated secretory phenotype (SASP). Unlike senolytics, senomorphics leave senescent cells viable but reduce their inflammatory output. Examples include rapamycin (reduces SASP through mTOR inhibition) and metformin (reduces inflammatory signaling).

Senolytics

Drugs that selectively induce apoptosis in senescent cells, which are resistant to normal cell death mechanisms. The first senolytics discovered were dasatinib plus quercetin (D+Q), and fisetin has also shown senolytic properties. By clearing senescent cell burden, senolytics aim to reduce SASP-driven inflammation and improve tissue function in aging organisms.

Stem Cell Exhaustion

A hallmark of aging marked by declining numbers and regenerative capacity of tissue-resident stem cells. This leads to impaired tissue maintenance and repair, manifesting as thinning skin, reduced muscle mass (sarcopenia), impaired immune function (thymic involution), and decreased wound healing. Growth factors, peptides (like thymosin beta-4), and stem cell niche modulation are being studied to counteract this decline.

Telomere Attrition

A hallmark of aging in which telomeres progressively shorten with each cell division due to the end-replication problem and oxidative damage. When telomeres reach a critical length, cells enter senescence or undergo apoptosis, reducing tissue regenerative capacity. Telomere shortening rate is influenced by genetics, oxidative stress, inflammation, and can be counteracted by telomerase activity.

---

Hormones and Endocrinology

ACTH (Adrenocorticotropic Hormone)

A 39-amino-acid peptide hormone secreted by the anterior pituitary that stimulates the adrenal cortex to produce cortisol and other glucocorticoids. ACTH release is regulated by CRH from the hypothalamus and is part of the hypothalamic-pituitary-adrenal (HPA) axis stress response. ACTH also has melanocyte-stimulating activity due to sharing the first 13 amino acids with alpha-MSH.

Cortisol

The primary glucocorticoid hormone produced by the adrenal cortex in response to ACTH stimulation. Cortisol regulates glucose metabolism, suppresses immune function, and mediates the body's stress response through the HPA axis. Chronically elevated cortisol (as in Cushing's syndrome or chronic stress) promotes insulin resistance, muscle wasting, immunosuppression, and accelerated aging.

Estrogen

A group of steroid hormones (primarily estradiol, estrone, estriol) produced mainly by the ovaries (and in smaller amounts by the adrenals and adipose tissue) that regulate female reproductive development and function. Estrogen also maintains bone density, cardiovascular health, brain function, and skin elasticity. Declining estrogen at menopause contributes to osteoporosis, cardiovascular risk, and various aging-related changes.

FSH (Follicle-Stimulating Hormone)

A glycoprotein gonadotropin secreted by the anterior pituitary that stimulates follicular growth in the ovaries and spermatogenesis in the testes. FSH release is regulated by GnRH and feedback from inhibin and sex steroids. Elevated FSH levels occur in menopause and have recently been implicated in bone loss and adiposity through direct peripheral effects.

Glucagon

A 29-amino-acid peptide hormone produced by pancreatic alpha cells that raises blood glucose by promoting hepatic glycogenolysis and gluconeogenesis. Glucagon opposes the actions of insulin and is critical for preventing hypoglycemia during fasting. Dual GLP-1/glucagon receptor agonists are being developed for obesity and metabolic disease treatment.

Growth Hormone (GH)

A 191-amino-acid protein secreted by anterior pituitary somatotrophs in a pulsatile pattern, predominantly during sleep. GH stimulates IGF-1 production, promotes linear growth in children, and regulates body composition, lipid metabolism, and tissue repair in adults. GH secretion declines with age (somatopause), and GH secretagogue peptides (GHRP-6, ipamorelin, hexarelin) are studied to restore youthful GH pulsatility.

IGF-1 (Insulin-Like Growth Factor 1)

A peptide hormone primarily produced by the liver in response to growth hormone stimulation. IGF-1 mediates many of GH's anabolic effects, promoting cell growth, proliferation, and survival through the IGF-1R and downstream PI3K/AKT and MAPK pathways. IGF-1 levels decline with age and are central to the GH/IGF-1 axis that regulates growth, metabolism, and longevity.

Insulin

A 51-amino-acid peptide hormone produced by pancreatic beta cells that is the primary regulator of blood glucose homeostasis. Insulin promotes glucose uptake into muscle and adipose tissue, stimulates glycogen synthesis, and inhibits hepatic gluconeogenesis. Insulin resistance is a hallmark of type 2 diabetes and metabolic syndrome, and the insulin/IGF-1 signaling pathway is one of the most conserved longevity-regulating pathways across species.

LH (Luteinizing Hormone)

A glycoprotein gonadotropin secreted by the anterior pituitary that triggers ovulation and progesterone production in females, and stimulates testosterone production by Leydig cells in males. LH surges are critical for reproductive function and are regulated by pulsatile GnRH input. GnRH agonists and antagonists manipulate LH secretion for fertility treatment and hormone-sensitive cancer therapy.

Melatonin

A neurohormone produced by the pineal gland primarily during darkness that regulates circadian rhythm and sleep-wake cycles. Melatonin also acts as a potent antioxidant, immune modulator, and oncostatic agent. Melatonin production declines with age, and supplementation is studied for sleep disorders, jet lag, neuroprotection, and as an adjunct in cancer therapy.

Oxytocin

A nine-amino-acid cyclic peptide hormone produced in the hypothalamus and released from the posterior pituitary. Known as the "bonding hormone," oxytocin stimulates uterine contractions during labor, milk ejection during lactation, and social bonding behaviors. Emerging research explores oxytocin's roles in wound healing, muscle regeneration, and as a potential anti-aging factor.

Prolactin

A peptide hormone secreted by the anterior pituitary that primarily stimulates milk production (lactation) after childbirth. Prolactin has over 300 known biological actions including immune regulation, osmoregulation, and reproductive behavior. Elevated prolactin (hyperprolactinemia) can suppress the HPG axis, causing hypogonadism, and is commonly caused by pituitary adenomas or dopamine-blocking medications.

Somatostatin

A cyclic peptide hormone produced in the hypothalamus, pancreatic delta cells, and gastrointestinal tract that broadly inhibits hormone secretion. It suppresses growth hormone, insulin, glucagon, TSH, and numerous GI hormones. Synthetic analogs (octreotide, lanreotide) are used to treat acromegaly and neuroendocrine tumors. Somatostatin's inhibitory action opposes GHRH-stimulated GH release.

Testosterone

The primary androgen produced mainly by testicular Leydig cells in males and in smaller amounts by the adrenals and ovaries in females. Testosterone drives male reproductive development, maintains muscle mass and bone density, regulates erythropoiesis, and influences mood and cognition. Age-related testosterone decline (andropause) contributes to sarcopenia, osteoporosis, and metabolic changes.

Thyroid Hormones (T3/T4)

Iodine-containing hormones (thyroxine/T4 and triiodothyronine/T3) produced by the thyroid gland that regulate basal metabolic rate, thermogenesis, growth, and development. T4 is the predominant circulating form, converted to the more active T3 in peripheral tissues by deiodinase enzymes. Thyroid dysfunction affects virtually every organ system and is common in aging populations.

---

Disease and Condition Terms

Alzheimer's Disease

A progressive neurodegenerative disorder characterized by extracellular amyloid-beta plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein. It is the most common cause of dementia, affecting memory, cognition, and eventually basic functions. Research peptides including humanin, DSIP, and semax are being studied for neuroprotective properties in Alzheimer's models.

Amyotrophic Lateral Sclerosis (ALS)

A progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord, leading to muscle weakness, atrophy, and eventually respiratory failure. ALS involves multiple pathogenic mechanisms including protein aggregation (TDP-43, SOD1), glutamate excitotoxicity, oxidative stress, and neuroinflammation. Neuroprotective peptides are being explored as potential therapeutic agents.

Atherosclerosis

A chronic inflammatory disease of arteries characterized by the buildup of lipid-rich plaques in the vessel wall. It develops through endothelial dysfunction, LDL oxidation, macrophage foam cell formation, and smooth muscle proliferation. Atherosclerosis is the underlying cause of most heart attacks and strokes, and involves complex interactions between inflammatory cytokines, immune cells, and vascular peptides.

Cachexia

A complex metabolic syndrome characterized by severe, involuntary loss of skeletal muscle mass (with or without fat loss) that cannot be fully reversed by nutritional support. It occurs in cancer, HIV/AIDS, heart failure, and COPD, and significantly increases mortality. GH secretagogues and ghrelin mimetics (anamorelin) are studied for their ability to counteract cancer-related cachexia.

Fibrosis

The excessive accumulation of extracellular matrix components, particularly collagen, resulting in tissue scarring and organ dysfunction. Fibrosis can affect the liver (cirrhosis), lungs (pulmonary fibrosis), kidneys, heart, and skin. Key mediators include TGF-beta, activated fibroblasts/myofibroblasts, and inflammatory cytokines. Anti-fibrotic peptides are an active area of research.

Inflammatory Bowel Disease (IBD)

A group of chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. IBD involves dysregulated immune responses against gut microbiota in genetically susceptible individuals. Peptides including BPC-157 and KPV (alpha-MSH fragment) are studied for their anti-inflammatory and mucosal healing properties in IBD models.

Ischemia

A condition in which insufficient blood supply to a tissue causes oxygen deprivation (hypoxia) and nutrient deficiency, leading to cellular injury and potentially necrosis. Ischemia-reperfusion injury occurs when blood flow is restored, generating reactive oxygen species that cause additional damage. Cytoprotective peptides including BPC-157 and thymosin beta-4 are studied for ischemia protection.

Multiple Sclerosis (MS)

An autoimmune disease in which the immune system attacks myelin sheaths surrounding nerve fibers in the central nervous system, causing demyelination, axonal damage, and neurological dysfunction. Symptoms vary widely but can include fatigue, vision problems, motor impairment, and cognitive changes. Immunomodulatory peptides and tolerogenic approaches are being explored as treatments.

NASH/NAFLD

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum from simple hepatic steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which includes inflammation and hepatocyte injury with risk of progression to cirrhosis. NASH is strongly associated with obesity and insulin resistance. GLP-1 receptor agonists (semaglutide) have shown promise in reducing liver fat and inflammation in NASH trials.

Obesity

A chronic metabolic disease characterized by excessive adipose tissue accumulation that impairs health. Obesity involves dysregulated energy balance, hormonal signaling (leptin resistance, insulin resistance), and neurobiological appetite control. GLP-1 receptor agonists (semaglutide, tirzepatide) have transformed obesity treatment, achieving weight loss of 15-20% or more in clinical trials.

Osteoporosis

A skeletal disorder characterized by reduced bone mineral density and deterioration of bone microarchitecture, leading to increased fracture risk. Osteoporosis results from an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Hormonal changes (menopause, andropause), GH/IGF-1 decline, and chronic inflammation contribute to age-related bone loss.

Parkinson's Disease

A progressive neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra, characterized by motor symptoms (tremor, rigidity, bradykinesia) and non-motor features (cognitive decline, autonomic dysfunction, mood disorders). Alpha-synuclein protein aggregation (Lewy bodies) is a pathological hallmark. Neuroprotective peptides are being investigated as disease-modifying therapies.

Retinitis Pigmentosa

A group of inherited retinal dystrophies characterized by progressive degeneration of photoreceptor cells (primarily rods, then cones), leading to night blindness and tunnel vision, potentially progressing to complete blindness. The condition involves multiple genetic mutations affecting photoreceptor function and survival. Neuroprotective peptides including NAP (davunetide) and CNTF are being studied for photoreceptor preservation.

Sarcopenia

Age-related loss of skeletal muscle mass, strength, and function that begins around age 30 and accelerates after age 60. Contributing factors include declining GH/IGF-1, testosterone, physical inactivity, chronic inflammation, and satellite cell dysfunction. GH secretagogue peptides, myostatin inhibitors, and follistatin-related therapies are being explored to counteract sarcopenia.

Type 2 Diabetes

A metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction, resulting in chronic hyperglycemia. It is strongly associated with obesity, physical inactivity, and genetic predisposition. GLP-1 receptor agonists (semaglutide, tirzepatide) and GIP/GLP-1 dual agonists have become cornerstone treatments, improving glycemic control while promoting weight loss and potentially reducing cardiovascular risk.

---

Research Methods

Double-Blind Study

A clinical trial design in which neither the participants nor the investigators know which treatment (active drug or placebo) each participant is receiving until the study is complete. Double-blinding minimizes expectation bias and observer bias, strengthening the validity of study findings. It is considered the gold standard in clinical trial methodology.

ED50

The effective dose of a drug that produces the desired therapeutic effect in 50% of the test population. ED50 is used to establish dose-response relationships in vivo and is distinct from EC50, which is determined in vitro. The ratio of LD50 to ED50 provides the therapeutic index, a measure of drug safety.

ELISA (Enzyme-Linked Immunosorbent Assay)

A plate-based assay technique used to detect and quantify peptides, proteins, antibodies, and hormones. ELISA uses antibody-antigen interactions and enzyme-linked color reactions for detection. It is widely used in peptide research to measure hormone levels, cytokine concentrations, and biomarker quantities in biological samples.

Ex Vivo

Experiments conducted on tissue taken from a living organism and studied in an external environment with minimal alteration of natural conditions. Ex vivo approaches bridge the gap between in vitro cell culture and in vivo whole-organism studies, maintaining tissue architecture and cell-cell interactions while allowing controlled experimental manipulation.

Flow Cytometry

A technique that passes cells in a fluid stream through a laser beam to measure physical and chemical characteristics of cell populations. Fluorescent antibodies or dyes label specific cell surface markers or intracellular proteins, enabling identification and quantification of cell types, cell cycle analysis, and apoptosis detection. It is essential in immunology research for characterizing immune cell populations.

Immunohistochemistry (IHC)

A technique that uses antibodies to detect specific proteins in tissue sections, allowing visualization of protein expression and localization in their anatomical context. IHC is combined with microscopy to examine receptor distribution, cell type identification, and disease pathology. It is widely used in cancer diagnosis and peptide receptor mapping in research.

In Vitro

Experiments performed outside a living organism, typically in test tubes, cell culture plates, or other laboratory vessels. In vitro studies allow controlled investigation of specific biological mechanisms but may not fully reflect the complexity of in vivo responses. Cell-based assays, receptor binding studies, and enzyme kinetics are common in vitro approaches in peptide research.

In Vivo

Experiments conducted within a living organism, providing the most physiologically relevant data about drug effects, pharmacokinetics, and safety. In vivo studies in animal models are required before human clinical trials and assess whole-organism responses including absorption, distribution, metabolism, excretion, and systemic effects. They complement but cannot be fully replaced by in vitro studies.

LD50

The lethal dose of a substance that kills 50% of a test animal population, a measure of acute toxicity. LD50 testing has become less common due to ethical concerns and has been partially replaced by alternative methods. When reported, LD50 helps establish the margin of safety for a compound and is used in the calculation of the therapeutic index.

PCR (Polymerase Chain Reaction)

A technique that amplifies specific DNA sequences millions of times using cycles of denaturation, primer annealing, and DNA polymerase extension. Quantitative PCR (qPCR) measures gene expression levels, while reverse-transcription PCR (RT-PCR) first converts mRNA to cDNA. PCR is used in peptide research to measure gene expression changes in response to peptide treatment.

Phase I / II / III Clinical Trials

The three main stages of human clinical trials for drug development. Phase I tests safety, dosing, and side effects in a small group of healthy volunteers (20-100). Phase II evaluates efficacy and further assesses safety in patients with the target condition (100-300). Phase III confirms efficacy in large patient populations (1000-3000+) and is required for regulatory approval. Each phase builds on data from the previous one.

Placebo-Controlled

A study design in which the control group receives an inactive treatment (placebo) identical in appearance to the active treatment. Comparing outcomes between active and placebo groups isolates the drug's true effect from the placebo response and natural disease course. Placebo-controlled trials are essential for establishing efficacy, particularly for subjective endpoints.

Randomized Controlled Trial (RCT)

The gold standard study design in which participants are randomly assigned to treatment or control groups, minimizing selection bias and confounding variables. Randomization ensures that known and unknown factors are distributed equally between groups. RCTs combined with blinding and placebo controls provide the strongest evidence for therapeutic efficacy and safety.

Western Blot

A laboratory technique used to detect specific proteins in a tissue homogenate or cell lysate by separating proteins by size through gel electrophoresis, transferring them to a membrane, and probing with specific antibodies. Western blotting is used in peptide research to assess protein expression levels, post-translational modifications, and signaling pathway activation (phospho-specific antibodies).

---

Common Acronyms in Peptide Research

BBB (Blood-Brain Barrier)

The selective permeability barrier formed by brain capillary endothelial cells joined by tight junctions, pericytes, and astrocyte end-feet. The BBB prevents most blood-borne substances from entering the brain while allowing essential nutrients and gases to pass. It represents a major challenge for CNS drug delivery, and peptide-based transport strategies (shuttle peptides, receptor-mediated transcytosis) are being developed to cross it.

CNS (Central Nervous System)

The brain and spinal cord, which integrate sensory information, coordinate motor functions, and serve as the center of higher cognitive functions. The CNS is protected by the blood-brain barrier and contains unique cell types including neurons, astrocytes, oligodendrocytes, and microglia. Many neuroprotective peptides (semax, selank, cerebrolysin, dihexa) target CNS function.

DPP-IV (Dipeptidyl Peptidase-4)

A serine protease that rapidly degrades incretin hormones (GLP-1 and GIP) by cleaving the N-terminal dipeptide. DPP-IV inhibitors (sitagliptin, saxagliptin) are oral diabetes medications that prolong endogenous incretin activity. DPP-IV resistance is a key feature engineered into long-acting GLP-1 receptor agonists like semaglutide and liraglutide.

ECM (Extracellular Matrix)

The non-cellular structural framework composed of proteins (collagen, elastin, fibronectin) and polysaccharides (hyaluronic acid, proteoglycans) that surrounds cells in tissues. The ECM provides physical scaffolding, biochemical signaling, and mechanical cues that regulate cell behavior. ECM composition changes with age and disease, and peptides like GHK-Cu promote ECM remodeling and repair.

EMA (European Medicines Agency)

The regulatory body responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union. EMA's Committee for Medicinal Products for Human Use (CHMP) issues marketing authorization opinions for drug approval. EMA and FDA harmonize many regulatory standards but maintain independent approval processes.

FDA (Food and Drug Administration)

The United States federal agency responsible for regulating drugs, biologics, medical devices, food safety, and cosmetics. The FDA's approval process requires demonstration of safety and efficacy through preclinical studies and phased clinical trials. FDA-approved peptide therapeutics include semaglutide, insulin analogs, teriparatide, and numerous others.

GI (Gastrointestinal)

Relating to the gastrointestinal tract, the organ system from mouth to anus responsible for digestion, nutrient absorption, and waste elimination. The GI tract is a major site of peptide hormone production (GLP-1, GIP, ghrelin, cholecystokinin) and is the primary barrier to oral peptide bioavailability. GI-protective peptides like BPC-157 are studied for mucosal healing.

GRAS (Generally Recognized as Safe)

A designation by the FDA indicating that a substance (food additive or ingredient) is considered safe by qualified experts based on its history of common use in food or published scientific evidence. GRAS substances do not require pre-market approval. Some amino acids and simple peptides used in supplements carry GRAS status.

HPA Axis (Hypothalamic-Pituitary-Adrenal Axis)

The neuroendocrine system linking the hypothalamus (CRH), anterior pituitary (ACTH), and adrenal cortex (cortisol) that coordinates the body's stress response. HPA axis activation increases cortisol to mobilize energy and suppress inflammation. Chronic HPA axis dysregulation (from prolonged stress) contributes to immune suppression, metabolic dysfunction, and accelerated aging.

HPG Axis (Hypothalamic-Pituitary-Gonadal Axis)

The neuroendocrine system linking the hypothalamus (GnRH), anterior pituitary (FSH, LH), and gonads (testosterone, estrogen) that regulates reproductive function. Pulsatile GnRH secretion maintains HPG axis activity, while continuous GnRH exposure causes desensitization. HPG axis decline with aging contributes to menopause, andropause, and associated metabolic changes.

IFN-gamma (Interferon Gamma)

A cytokine produced primarily by T-cells and NK cells that is critical for innate and adaptive immunity. IFN-gamma activates macrophages, enhances antigen presentation, promotes Th1 immune responses, and has direct antiviral and antitumor activity. It is used therapeutically in chronic granulomatous disease and is modulated by immunomodulatory peptides including thymosin alpha-1.

IL-1 / IL-2 / IL-6 / IL-10 (Interleukins)

A family of cytokines that mediate communication between immune cells. IL-1 is a pro-inflammatory mediator in innate immunity and inflammasome activation. IL-2 drives T-cell proliferation and is used in cancer immunotherapy. IL-6 has both pro- and anti-inflammatory roles and is elevated in chronic inflammation and aging. IL-10 is a potent anti-inflammatory cytokine that suppresses immune activation and maintains tissue homeostasis.

MMP (Matrix Metalloproteinase)

A family of zinc-dependent endopeptidases that degrade extracellular matrix components. MMPs (collagenases, gelatinases, stromelysins) play essential roles in tissue remodeling, wound healing, and angiogenesis. Excessive MMP activity contributes to cancer metastasis, arthritis, and skin aging. MMP activity is balanced by tissue inhibitors of metalloproteinases (TIMPs) and is influenced by peptides including GHK-Cu.

NO (Nitric Oxide)

A gaseous signaling molecule produced by nitric oxide synthase (NOS) enzymes from L-arginine. NO regulates vasodilation (lowering blood pressure), neurotransmission, immune defense (macrophage killing), and platelet aggregation. Endothelial NO production declines with age and is implicated in cardiovascular disease. BPC-157 is studied for its effects on NO-mediated pathways.

PK/PD (Pharmacokinetics/Pharmacodynamics)

The integrated study of drug concentration-time profiles (PK) and concentration-effect relationships (PD). PK/PD modeling characterizes how a drug's absorption, distribution, metabolism, and excretion relate to its therapeutic and toxic effects over time. Understanding PK/PD is essential for peptide dose optimization, particularly given the rapid clearance and short half-lives of most peptides.

PNS (Peripheral Nervous System)

All neural structures outside the brain and spinal cord, including cranial nerves, spinal nerves, and the autonomic nervous system. The PNS connects the CNS to limbs and organs, carrying sensory information inward and motor commands outward. Neuroprotective peptides including BPC-157 and NGF are studied for peripheral nerve repair and regeneration.

ROS (Reactive Oxygen Species)

Chemically reactive molecules containing oxygen, including superoxide, hydrogen peroxide, and hydroxyl radicals, generated as byproducts of mitochondrial respiration and by specific enzymes (NADPH oxidase). While low-level ROS serve as signaling molecules, excessive ROS cause oxidative damage to DNA, proteins, and lipids. Antioxidant defense systems (SOD, catalase, glutathione, Nrf2 pathway) counteract ROS, and oxidative stress is implicated in aging and numerous diseases.

SNAC (Sodium N-[8-(2-Hydroxybenzoyl)Amino] Caprylate)

An absorption enhancer used in the oral formulation of semaglutide (Rybelsus). SNAC creates a localized increase in pH around the tablet in the stomach, protecting the peptide from pepsin degradation and promoting transcellular absorption across the gastric epithelium. It represents a breakthrough in oral peptide delivery technology, enabling the first orally administered GLP-1 receptor agonist.

TNF-alpha (Tumor Necrosis Factor Alpha)

A pro-inflammatory cytokine produced primarily by macrophages that plays central roles in systemic inflammation, immune regulation, and apoptosis. TNF-alpha activates NF-kappaB signaling and is a key mediator in autoimmune diseases (rheumatoid arthritis, IBD, psoriasis). TNF inhibitors (infliximab, adalimumab, etanercept) are among the most commercially successful biologic therapies.

VEGF (Vascular Endothelial Growth Factor)

A signaling protein family (VEGF-A, -B, -C, -D, PlGF) that stimulates angiogenesis, the formation of new blood vessels from existing vasculature. VEGF-A binding to VEGFR2 is the primary angiogenic signal, promoting endothelial cell proliferation, migration, and survival. Anti-VEGF therapies (bevacizumab, ranibizumab) are used in cancer and retinal diseases, while pro-angiogenic approaches are explored for ischemic tissue repair.